SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TheSlowLane who wrote (148)5/13/1997 10:06:00 PM
From: NeuroInvestment   of 675
 
I doubt that yet another roadshow presentation is going to stir up much. While the next news should be the long awaited Glial Growth Factor collaboration (and apparently there has been some ambiguity about patent protection slowing that process), the market as a whole is waiting on Cerestat. However, even when an interim analysis is done this summer, it will not be on the primary endpoint, because to open up that scale would reduce statistical power later on. The scale that will be assessed is not likely to give the kind of dramatic contrasts that would warrant stopping the study and going for early approval. Thus definitive data is not likely until sometime 4Q. I am optimistic that Cerestat will work with an acceptable side effect profile, and thus far no safety concerns have been raised in the Phase III's. But nearterm stock movements are likely to be minor. NeuroInvestment
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News